Fibrovein

Maa: Uusi-Seelanti

Kieli: englanti

Lähde: Medsafe (Medicines Safety Authority)

Aktiivinen ainesosa:

Sodium tetradecyl sulfate 1%{relative}

Saatavilla:

InterMed Medical Ltd

INN (Kansainvälinen yleisnimi):

Sodium tetradecyl sulfate 1% w/v

Annos:

1 %

Lääkemuoto:

Solution for injection

Koostumus:

Active: Sodium tetradecyl sulfate 1%{relative} Excipient: Benzyl alcohol Dibasic sodium phosphate Monobasic potassium phosphate Sodium hydroxide Water for injection

Kpl paketissa:

Ampoule, glass, 2ml, 5 dose units

luokka:

Prescription

Prescription tyyppi:

Prescription

Valmistaja:

Cambrex Karlskoga AB

Käyttöaiheet:

The treatment of varicose veins of the leg by injection sclerotherapy.

Tuoteyhteenveto:

Package - Contents - Shelf Life: Ampoule, glass, 2ml - 5 dose units - 36 months from date of manufacture stored at or below 25°C

Valtuutus päivämäärä:

1969-12-31

Valmisteyhteenveto

NEW ZEALAND DATASHEET
1 PRODUCT NAME
FIBROVEIN
3.0%, 1.0%, 0.5% and 0.2% intravenous injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Sodium Tetradecyl Sulphate 3.0%, 1.0%, 0.5% and 0.2% intravenous
injection
Contains benzyl alcohol 20mg/ml. For a full list of excipients, see
section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless, sterile solution.
pH 7.5 – 7.9.
Osmolarity 247 – 273 mOsm/kg.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Fibrovein
3%
and
1%:
For
the
treatment
of
varicose
veins
of
the
leg
by
injection
sclerotherapy.
Fibrovein 0.5%: For the treatment of varicose veins and venous flares
of the leg by injection
sclerotherapy.
Fibrovein 0.2%: For the treatment of minor venules and spider veins
(venous flares) by
injection sclerotherapy.
4.2 Dose and method of administration
Fibrovein is for intravenous use only. The strength of solution
required depends on the size
and degree of varicosity. Spider veins should only be treated with the
0.2%, reticular veins
with 0.5%, the 1% solution will be found most useful for small to
medium varicosities and the
3% solution for larger varicosities. The size of non- visible varicose
veins should be
measured under ultrasound.
The sclerosant should be administered intravenously in small aliquots
at multiple sites along
the vein to be treated either as a liquid or as a sclerosant/air
mixture (foam), for the
treatment of larger veins with the 1% and 3% solutions. The objective
is to achieve optimal
destruction of the vessel wall with the minimum concentration of
sclerosant necessary for a
clinical result. If the concentration is too high necrosis or other
adverse sequelae may occur.
RECOMMENDED DOSES AND DOSAGE SCHEDULES:
ADULTS
Fibrovein 3.0%: 0.5 to 1.0ml of 3.0% Fibrovein injected intravenously
at each of 4 sites
(maximum 4ml).
Fibrovein 1.0%: 0.25 to 1.0ml of 1.0% Fibrovein injected intravenously
into the lumen of an
isolated
segment
of
emptied
superficial
vein,
followed
by
immediate
compression.
A
maximum of 10 sites (10ml total) m